Clinical Trial Update: Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528 [Phase 3]

View source ↗

Summary

Open-label extension study update for REQUIP PR in Parkinson disease subjects from a prior Phase 3 trial; study completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• REQUIP PR (ropinirole prolonged release)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Parkinson Disease | Phase 3 | Status: COMPLETED | Results posted: 2012-12-13